Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine

Catia T Perciani, Walter Jaoko, Sharon Walmsley, Bashir Farah, Salaheddin M Mahmud, Mario Ostrowski, Omu Anzala, Kavi-Icr Team, Kelly S MacDonald, Catia T Perciani, Walter Jaoko, Sharon Walmsley, Bashir Farah, Salaheddin M Mahmud, Mario Ostrowski, Omu Anzala, Kavi-Icr Team, Kelly S MacDonald

Abstract

Introduction: A protective HIV vaccine would be expected to induce durable effector immune responses at the mucosa, restricting HIV infection at its portal of entry. We hypothesise that use of varicella-zoster virus (VZV) as an HIV delivery vector could generate sustained and robust tissue-based immunity against HIV antigens to provide long-term protection against HIV. Given that HIV uniquely targets immune-activated T cells, the development of human vaccines against HIV must also involve a specific examination of the safety of the vector. Thus, we aim to evaluate the effects of VZV vaccination on the recipients' immune activation state, and on VZV-specific circulating humoral and cellular responses in addition to those at the cervical and rectal mucosa.

Methods and analysis: This open-label, randomised, longitudinal crossover study includes healthy Kenyan VZV-seropositive women at low risk for HIV infection. Participants receive a single dose of a commercial live-attenuated VZVOka vaccine at either week 0 (n=22) or at week 12 (n=22) of the study and are followed for 48 and 36 weeks postvaccination, respectively. The primary outcome is the change on cervical CD4+ T-cell immune activation measured by the coexpression of CD38 and HLA-DR 12 weeks postvaccination compared with the baseline (prevaccination). Secondary analyses include postvaccination changes in VZV-specific mucosal and systemic humoral and cellular immune responses, changes in cytokine and chemokine measures, study acceptability and feasibility of mucosal sampling and a longitudinal assessment of the bacterial community composition of the mucosa.

Ethics and dissemination: The study has ethical approval from Kenyatta National Hospital/University of Nairobi Ethics and Research Committee, the University of Toronto Research Ethics Board and by Kenyan Pharmacy and Poisons Board. Results will be presented at conferences, disseminated to participants and stakeholders as well as published in peer-reviewed journals.

Trial registration number: NCT02514018. Pre-results.

Keywords: HIV vaccine; herpes zoster; herpesviridae infections; immune activation; mucosal immunity; varicella-zoster virus; virus diseases.

Conflict of interest statement

Competing interests: SMM has received grants for unrelated studies from GSK, Merck, Pfizer and Sanofi, and served on advisory boards for GSK and Pfizer.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Schematic representation of enrolment and follow-up for KAVI-VZV-001 trial. (A) Immediate group and (B) delayed group. Immediate group receive a single dose of VZVOka vaccine at week 0 and delayed group at week 12. Participants are followed-up for a period of 36–48 weeks after receiving the vaccine. VZV, varicella-zoster virus.

References

    1. McMichael AJ, Borrow P, Tomaras GD, et al. . The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010;10:11–23. 10.1038/nri2674
    1. Hansen SG, Ford JC, Lewis MS, et al. . Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011;473:523–7. 10.1038/nature10003
    1. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med 2012;63:95–111. 10.1146/annurev-med-042010-085643
    1. Hansen SG, Piatak M, Ventura AB, et al. . Immune clearance of highly pathogenic SIV infection. Nature 2013;502:100–4. 10.1038/nature12519
    1. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996;9:361–81.
    1. Heininger U, Seward JF. Varicella. Lancet 2006;368:1365–76. 10.1016/S0140-6736(06)69561-5
    1. Chen JJ, Gershon AA, Li Z, et al. . Varicella zoster virus (VZV) infects and establishes latency in enteric neurons. J Neurovirol 2011;17:578–89. 10.1007/s13365-011-0070-1
    1. Krause PR, Klinman DM. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat Med 2000;6:451–4. 10.1038/74715
    1. Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010;342:341–57. 10.1007/82_2010_31
    1. Schünemann S, Mainka C, Wolff MH. Subclinical reactivation of varicella-zoster virus in immunocompromised and immunocompetent individuals. Intervirology 1998;41(2-3):98–102. 10.1159/000024920
    1. Gershon AA, Katz SL. Perspective on live varicella vaccine. J Infect Dis 2008;197(Suppl 2):S242–5. 10.1086/522151
    1. Gershon AA, Gershon MD. Perspectives on vaccines against varicella-zoster virus infections. Curr Top Microbiol Immunol 2010;342:359–72. 10.1007/82_2010_12
    1. Takahashi M, Asano Y, Kamiya H, et al. . Development of varicella vaccine. J Infect Dis 2008;197(Suppl 2):S41–4. 10.1086/522132
    1. Oxman MN, Levin MJ, Johnson GR, et al. . A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–84. 10.1056/NEJMoa051016
    1. Simberkoff MS, Arbeit RD, Johnson GR, et al. . Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 2010;152:545–54. 10.7326/0003-4819-152-9-201005040-00004
    1. Levin MJ, Oxman MN, Zhang JH, et al. . Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008;197:825–35. 10.1086/528696
    1. Gray WL. Recombinant varicella-zoster virus vaccines as platforms for expression of foreign antigens. Adv Virol 2013;2013:1–8. 10.1155/2013/219439
    1. Schub D, Janssen E, Leyking S, et al. . Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection. J Infect Dis 2015;211:600–12. 10.1093/infdis/jiu500
    1. Sei JJ, Cox KS, Dubey SA, et al. . Effector and central memory poly-functional CD4(+) and CD8(+) T Cells are boosted upon ZOSTAVAX vaccination. Front Immunol 2015;6:553 10.3389/fimmu.2015.00553
    1. Nagaike K, Mori Y, Gomi Y, et al. . Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coli. Vaccine 2004;22:4069–74. 10.1016/j.vaccine.2004.03.062
    1. Cohen JI. VZV: molecular basis of persistence (latency and reactivation) : Arvin A, Campadelli-Fiume G, Mocarski E, Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge: Cambridge University Press, 2007.
    1. Sen N, Mukherjee G, Arvin AM. Single cell mass cytometry reveals remodeling of human T cell phenotypes by varicella zoster virus. Methods 2015;90:85–94. 10.1016/j.ymeth.2015.07.008
    1. Gershon AA, Chen J, Gershon MD. A model of lytic, latent, and reactivating varicella-zoster virus infections in isolated enteric neurons. J Infect Dis 2008;197(Suppl 2):S61–5. 10.1086/522149
    1. Buchbinder SP, Mehrotra DV, Duerr A, et al. . Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881–93. 10.1016/S0140-6736(08)61591-3
    1. Duerr A, Huang Y, Buchbinder S, et al. . Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 2012;206:258–66. 10.1093/infdis/jis342
    1. Lajoie J, Kimani M, Plummer FA, et al. . Association of sex work with reduced activation of the mucosal immune system. J Infect Dis 2014;210:319–29. 10.1093/infdis/jiu023
    1. Lajoie J, Juno J, Burgener A, et al. . A distinct cytokine and chemokine profile at the genital mucosa is associated with HIV-1 protection among HIV-exposed seronegative commercial sex workers. Mucosal Immunol 2012;5:277–87. 10.1038/mi.2012.7
    1. Nkwanyana NN, Gumbi PP, Roberts L, et al. . Impact of human immunodeficiency virus 1 infection and inflammation on the composition and yield of cervical mononuclear cells in the female genital tract. Immunology 2009;128:e746–57. 10.1111/j.1365-2567.2009.03077.x
    1. Carnathan DG, Wetzel KS, Yu J, et al. . Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques. Proc Natl Acad Sci U S A 2015;112:518–23. 10.1073/pnas.1407466112
    1. Mir KD, Gasper MA, Sundaravaradan V, et al. . SIV infection in natural hosts: resolution of immune activation during the acute-to-chronic transition phase. Microbes Infect 2011;13:14–24. 10.1016/j.micinf.2010.09.011
    1. Zhang ZQ, Wietgrefe SW, Li Q, et al. . Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci U S A 2004;101:5640–5. 10.1073/pnas.0308425101
    1. Meditz AL, Haas MK, Folkvord JM, et al. . HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo. J Virol 2011;85:10189–200. 10.1128/JVI.02529-10
    1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. . Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209–20. 10.1056/NEJMoa0908492
    1. Kim JH, Rerks-Ngarm S, Excler JL, et al. . HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010;5:428–34. 10.1097/COH.0b013e32833d17ac
    1. Brown SA, Surman SL, Sealy R, et al. . Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials. Viruses 2010;2:435–67. 10.3390/v2020435
    1. Haynes BF. New approaches to HIV vaccine development. Curr Opin Immunol 2015;35:39–47. 10.1016/j.coi.2015.05.007
    1. McMichael AJ, Haynes BF. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol 2012;13:423–7. 10.1038/ni.2264

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅